Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

  • Technology appraisal guidance
  • TA1103
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence